Introduction: Intrinsic breast cancer subtypes (e.g., Normal-like, Luminal A/B, HER2-enriched, Triple Negative) vary in their responsiveness to neoadjuvant chemotherapy (NACT) and are associated with differing long-term prognosis. Expression dis-regulation of critical regulatory pathways partially accounts for variance in cancer phenotype…

Introduction: Finalizing the treatment plan to utilize on a cancer patient continues to be a collaborative process between the patient and clinician, often with input from the patient’s family. By referencing the tumor size and location from radiology reports and…

Background: A single neuron cannot think, just as a single hepatocyte cannot filter blood. The functions of the tissues that make up our bodies are emergent, depending on both their constituent cells’ internal biology, as well as how they interact…

Introduction: When considering the use of NACT for breast cancer, healthcare providers and patients must weigh the risks associated with different potential standard of care (SoC) treatment regimens against the likelihood of achieving a desired outcome. The decision of treatment…

Background: Racial disparities in breast cancer incidence and clinical outcome have become increasingly recognized. In particular, African American (AA) patients have higher mortality rates than other racial groups. Research into these racial disparities has primarily focused on socioeconomic determinants, with…